To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...
Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure ...
BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity ...